Material and Method: Eighty-seven patients with culture-positive sepsis (Group I, n =26) or clinical sepsis (Group II, n =61) were enrolled the study. The control group (Group III) consisted of 42 non-septic healthy neonates. Demographic data and laboratory results of the cases were examined. Clinical outcomes (survival or death) were also recorded.

Results: No statistically significant difference was found between the groups in terms of gender, gestational age and birth weight. Six of eight septic patients (75%) with elevated cTnI died. Conversely, 13 of other septic patients (11%) with normal cTnI levels died. Hence, the mortality rate was statistically significantly higher in patients with elevated cTnI levels (p <0.001). This study revealed that the cTnI cut-off value in neonates was 0.13 ng/ml (sensitivity 89.5%, specificity 90.9%). A 0.1-unit increase in cTnI level increased the risk of death by 1.4 times (p =0.012). However, no statistically significant difference was observed between surviving and deceased patients in terms of CK-MB levels (15.8% and 11.8%, respectively) (p >0.05).

Conclusion: There is a significant relationship between elevated cTnI levels and mortality in septic neonates. However, further multicenter studies with larger populations are needed to determine the relationship between cTnI levels and long-term prognosis in septic neonates.

Multiple organ failure, an important finding in sepsis patients, is a clinical picture characterized by the deterioration of respiratory, liver, kidney, hematological and cardiac functions. Clinical and laboratory findings vary depending on the affected organ. Neonatal sepsis has high mortality rates and causes serious complications such as intraventricular hemorrhage, bronchopulmonary dysplasia, retinopathy of prematurity, and neurodevelopmental disability ⁴. Hypotension and hypoperfusion due to cardiac dysfunction cause end-organ damage. Cardiac functions therefore affect all organ systems, and early detection of cardiac dysfunction and initiation of necessary treatments will contribute to prognosis ⁵.

In many studies, cardiac troponin I (cTnI) and creatine kinase-myocardial band (CK-MB) levels have been investigated as indicators of cardiac damage, especially in adults ^5,6. Some of these have shown that cTnI and CK-MB levels may be useful in demonstrating cardiac functions and predicting long-term prognosis ^7,8. Adult studies have found that cTnI levels are increased by 60% in septic patients with high mortality risks. Increased troponin levels have been associated with a 2- to 5-fold increased mortality risk even in septic patients without known cardiovascular disease ⁹. Cardiac TnI emerges in association with increased ventricular wall permeability and damage to cardiomyocytes during sepsis-associated cardiac stress. It has been reported that cTnI and CK-MB biomarkers can be used to provide information about neonatal cardiac functions and can be helpful not only in the diagnosis stage but also in monitoring the response to treatment. Cardiac biomarker levels in neonates have been investigated in various diseases such as perinatal asphyxia, sepsis, congenital heart diseases and respiratory distress. Studies have shown that normal ranges of cTnI may vary depending on variables such as adaptation of cTnI to postnatal circulation, age, gender, measurement technique and kit used ^10,11. This situation limits the practical clinical use of cardiac biomarkers in newborn babies.

Therefore, this study aimed to investigate the relationship between cardiac biomarker (cTnI and CK-MB) levels and prognosis in septic neonates.

Preterm (<37 gestational weeks) and term (>37 gestational weeks) newborns who underwent Töllner sepsis scoring due to suspicion of sepsis over a 46-month period between 2015 and 2018 and who met the inclusion criteria were prospectively enrolled in the study. Newborns with major congenital anomaly, inborn error of metabolism, congenital heart disease or cardiac dysrhythmia, asphyxia, those requiring short-term observation in the neonatal intensive care unit due to non-septic conditions (such as hypoglycemia, jaundice, transient tachypnea of the newborn, and other respiratory causes) were excluded from the study.

Patients with suspected sepsis were evaluated according to the "Töllner sepsis scoring" system ¹². Accordingly, cases scoring <5 were evaluated as "not suspected sepsis", those scoring 5-10 as "suspected sepsis", and those scoring >10 as "probable sepsis". Among the individuals in the probable sepsis group, those from whom bacteria were isolated in their blood cultures constituted the "proven sepsis" subgroup, and those from whom bacteria could not be isolated constituted the "clinical sepsis" subgroup. In addition, these patients were divided into groups I, II and III, respectively, as cases with bacterial isolation in blood culture or a Töllner sepsis score of >10, cases with a Töllner sepsis score between 5 and 10, and non-septic healthy newborns with a Töllner sepsis score of <5.

Neonatal sepsis was classified as EOS or LOS according to the time of onset. EOS describes neonatal sepsis that begins at ≤72 hours of life, while LOS describes neonatal sepsis that occurs at >72 hours of life ¹³. Infants born at <37 weeks of gestational age were considered preterm, and those born at ≥37 weeks were considered term neonates. Demographic data (gestational age, postnatal age, gender, age at diagnosis), laboratory test results (complete blood count, C-reactive protein (CRP), cTnI, CK-MB, blood gas analysis and lactate) and culture-antibiogram results (blood, urine and CSF) were recorded in previously prepared study forms. The patient's clinical outcomes (survival or death) and short- and long-term prognoses (epilepsy, neuromotor disability, vision-hearing problems, etc.) were also recorded.

Blood samples were taken and placed in 1 ml EDTA tubes and 1 ml dry tubes for sepsis evaluation. In addition to routine tests (for example, complete blood count, liver and kidney function tests and blood sugar, etc.), cTnI and CK-MB were investigated from blood samples placed in dry tubes. For micro CRP, 0.5 ml of blood was taken into a special pipette. About 0.5 ml blood was taken with a capillary blood gas pipette for blood gas analysis, and 2 ml blood sample was taken for blood culture. Micro CRP measurements were performed using a Quikread CRP device (Orion Diagnostica Oy, Espoo, Finland) installed in our unit. An ABL800 FLEX blood gas analysis device (Radiometer Medical ApS, Bronshoj, Denmark) was used for lactate and pH measurement. Complete blood count was performed with the ADVIA 2120i analyzer (Siemens AG, Erlangen, Germany). Creatine kinase-myocardial band and LDH were investigated with the ADVIA 2400 device (Siemens Healthcare GmbH, Nuremberg, Germany) and cTnI with the ADVIA Centaur XP device (Siemens Healthcare GmbH, Nuremberg, Germany). Creatine kinase-myocardial band values >40 U/L were considered positive and the reference range specified by our biochemistry laboratory was adopted. There is no limit that can be safely used in neonates. Studies to date for the cTnI reference range have yielded inconsistent results ¹⁰. Two studies with an upper limit of 0.9 ng/ml for cTnI were accepted as reference for our study ^9,14,15. BACTEC 9240 device (Becton Dickinson, New Jersey, USA) was used in the blood culture isolation procedures.

Statistical analysis
SPSS (Statistical Package for Social Sciences Windows version 22.0) software version was used for the statistical analysis. Descriptive statistics of continuous variables are presented as mean ± standard deviation. Normality controls for all variables were performed using the Shapiro-Wilk and Kolmogorov-Smirnov tests, and nonparametric methods were used in the analysis of variables that did not conform to normal distribution. The Mann-Whitney U test was used for two-group comparisons, the results being reported as Q1: first quartile, Q3: third quartile, and median values. Spearman's correlation coefficient was used to determine linear relationships. The chi-square test was applied in the analysis of categorical variables. A 15-day trial version of MedClac software was used to determine cut-off values, while Statistica 11 software was used for all remaining analyses. Mann-Whitney U tests were used to compare median values and chi-square tests for percentages. One-Way Analysis of Variance (ANOVA) was applied to determined causes of differences in the comparison of non-parametric multiple variables. Statistical significance (p value) was determined as 0.05 for all analyses.

The study included 87 septic patients (67.4%) (Group I + Group II) and 42 non-septic healthy neonates (32.6%) (Group III) admitted to the NICU of our hospital. Of the patients with clinical and laboratory findings suggestive of sepsis, 26 (29.9%) were in Group I (culture-proven sepsis) and 61 (70.1%) were in Group II (clinical sepsis). No statistically significant difference was observed between the groups in terms of gender, term-preterm ratio, gestational age and birth weight (p >0.05) (Table 1).

Click Here to Zoom

Table 1: Comparison of patient groups according to their demographic characteristics.

In terms of sepsis onset time, 13 (14.9%) patients were diagnosed with EOS and 74 (85.1%) patients were diagnosed with LOS. Blood culture was positive in 2 patients (15.3%) in the EOS group and in 24 patients (32.8%) in the LOS group. Accordingly, culture positivity in LOS cases was significantly higher than in EOS cases (p <0.001). When all sepsis cases were evaluated together, regardless of the time of sepsis onset, the most frequently isolated microorganism from blood culture was coagulase-negative staphylococcus (CoNS). Coagulase-negative staphylococcus was isolated from one of the two patients in the EOS group, and Klebsiella pneumoniae was isolated from the other. In terms of laboratory parameters, no significant difference was observed between the groups in terms of white blood cell (WBC) count and CK-MB levels, while significant differences were found between platelet count, CRP, lactate, and cTnI levels and pH value (Table 2).

Click Here to Zoom

Table 2: Comparison of laboratory results between patient groups.

Mortality rates in cases with high and normal CK-MB levels were 15.8% and 11.8%, respectively. Hence, no significant correlation was found between CK-MB levels and mortality rate (p >0.05). Median cTnI levels were 0.03 ng/mL (range, 0.01-1.27) in surviving patients and 0.267 ng/mL (range, 0.030-5.230) in deceased patients. In fact, cardiac TnI levels were significantly higher in deceased patients (p <0.001) (Table 3).

Click Here to Zoom

Table 3: "Cut off" values to predict the effects of laboratory parameters on mortality.

A significant effect of troponin value on mortality was found (p =0.012). It was found that a 0.1-unit increase in cTnI level increased the risk of death by 1.4 times (95% confidence interval 0.48-4.18). The specificity and sensitivity of cTnI and CK-MB in determining sepsis severity are shown in Figure 1 and Figure 2.

Click Here to Zoom

Figure 1: Specificity and sensitivity of cTnI in predicting the severity of neonatal sepsis.

Click Here to Zoom

Figure 2: Specificity and sensitivity of CK-MB in predicting the severity of neonatal sepsis.

Similarly, lactate level was also found to have a significant effect on mortality risk (p =0.025). Additionally, a significant difference was observed between surviving and deceased patients in terms of CRP level (p <0.001), platelet count (p =0.001) and pH value (p <0.001). Table 4 shows the effects of laboratory parameters on mortality.

Click Here to Zoom

Table 4: Effects of laboratory parameters on mortality.

Although the areas of use and reference ranges of cardiac biomarkers are well defined in adults, they are not yet clear in neonates. Biomarkers of myocardial damage can be detected from blood tests and these markers may develop not only in the disease state but also due to prenatal and postnatal causes such as exposure to acute or prolonged tocolytic therapy and physiological circulatory changes after birth. Studies have shown that cardiac troponin limits in healthy newborns are higher than in adults due to the factors mentioned above ^17,18. Creatine kinase-myocardial band, which is mostly of muscular origin and reflects perinatal stress or tissue damage, does not provide clear results about the stage of myocardial damage in the neonates, especially in the first days of life. However, increases in cardiac troponin above a certain physiological level may indicate myocardial involvement. Intracellular protein leakage and damage to the myocardial cell membrane are thought to be an important mechanism for blood cTnI levels ¹⁹. Cardiac biomarkers have been studied in many diseases such as perinatal asphyxia, patent ductus arteriosus, persistent pulmonary hypertension, sepsis and bronchopulmonary dysplasia to determine the severity of the disease and to predict the prognosis ²⁰.

Myocardial dysfunction caused by sepsis is a result of hemodynamic, molecular, metabolic and structural changes and is closely related to sepsis-related mortality and morbidity ^21,22. Increased cTnI levels are a common finding in patients with sepsis. In these cases, coronary angiography and autopsy results have shown that high cTnI may occur without significant findings in favor of coronary artery disease ²³. Peek et al. ²⁴ examined the levels of cTnI, cardiac troponin T (cTnT), creatinine kinase (CK) and CK-MB in newborn calves with experimentally induced sepsis with E. coli endotoxin. These researchers found a significant difference in cTnI and CK levels measured after endotoxemia compared to control and baseline levels. Oliveira et al. ²⁵ examined the effect of cTnI levels on survival in pediatric patients diagnosed with sepsis and septic shock and identified serum cTnI levels as the only variable associated with the severity of septic disease and mortality. In that study, CK-MB levels did not appear to have any effect on survival. Abdel-Hady et al. ⁶ demonstrated the diagnostic and prognostic use of cTnT and "total ejection isovolumic index (Tei)" in patients with sepsis. A positive correlation was observed between left and right ventricular Tei index and cTnT levels in patients with neonatal sepsis. Cardiac TnT concentrations and left ventricular Tei index were significantly higher in septic neonates who died than in survivors. Frencken et al. ²⁶ evaluated the relationship between cTnI levels and sepsis-related mortality and long-term (one-year) outcomes in septic patients. These researchers reported that increases in cTnI levels were associated with increased mortality rates in the first 14 days after sepsis, but not in subsequent days. An association between increased cTnI levels during sepsis and long-term cardiovascular disease in patients who survived a septic episode has been reported, and this association may predict cardiovascular morbidity after discharge.

Cardiac TnI levels, a sensitive marker of cardiac damage, were found to be significantly higher in the sepsis group in this study, and the mortality rate was correspondingly higher in patients with elevated cTnI levels. Previous studies have shown that cTnI levels can provide useful information about long-term prognosis. For example, Zheng et al. ²⁷ reported that elevated troponin levels in sepsis patients are a potential predictor of prognosis, including hospital and long-term mortality. Moreover, the researchers recommended that clinicians treating septic patients with elevated troponin levels should be more careful to avoid extra death. However, conflicting results have been reported regarding whether CK-MB levels can predict prognosis in neonatal diseases. Beydilli and Gökçe ²⁸ demonstrated that increases in serum cardiac biomarkers such as CK-MB, cTnI and NT-proBNP in newborn calves were indicative of sepsis-induced cardiac damage and dysfunction. In contrast, Kırbas et al. ²⁹ reported that CK-MB had low diagnostic performance than cTnI in detecting myocardial injury in newborn calves with sepsis. In our study, no significant difference was found between the sepsis group and the control group in terms of CK-MB levels. Similarly, no significant difference was found in mortality rates in patients with high CK-MB levels. In this study, the cTnI cut-off value was found to be 0.13, and a 0.1-unit increase in cTnI level increases the risk of mortality by 1.4 times.

The limitations of this study include the use of micro CRP in our unit and the fact that cytokines or biomarkers such as procalcitonin and IL-6 are not routinely studied in our hospital and therefore they were not included in our study. In addition, echocardiographic examination was not performed simultaneously with cTnI levels in all patients. Another limitation is that the relationship between cTnI levels and short-term complications and long-term sequelae could not be evaluated. Additionally, stronger results could have been obtained by including a larger number of patients in the study. A final limitation is that the results reflect those of only one center.

1) Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet 2017; 390: 1770-80.

2) Ozkan H, Cetinkaya M, Koksal N, Celebi S, Hacımustafaoglu M. Culture-proven neonatal sepsis in preterm infants in a neonatal intensive care unit over a 7 year period: coagulase-negative Staphylococcus as the predominant pathogen. Pediatr Int 2014; 56: 60-6.

3) Turhan EE, Gürsoy T, Ovalı F. Factors which affect mortality in neonatal sepsis. Turk Pediatri Ars 2015; 50: 170-5.

4) Kim SJ, Kim GE, Park JH, Lee SL, Kim CS. Clinical features and prognostic factors of early-onset sepsis: a 7.5-year experience in one neonatal intensive care unit. Korean J Pediatr 2019; 62: 36-41.

5) Awny MM, Tolba OA, Al-Biltagi MA, Al-Asy HM, El-Mahdy HS. Cardiac functions by tissue doppler and speckle tracking echocardiography in neonatal sepsis and its correlation with sepsis markers and cardiac troponin-T. J Pediatr Neonatal Care 2016; 5: 00184.

6) Abdel-Hady HE, Matter MK, El-Arman MM. Myocardial dysfunction in neonatal sepsis: a tissue Doppler imaging study. Pediatr Crit Care Med 2012; 13: 318-23.

7) Montaldo P, Rosso R, Chello G, Giliberti P. Cardiac troponin I concentrations as a marker of neurodevelopmental outcome at 18 months in newborns with perinatal asphyxia. J Perinatol 2014; 34: 292-5.

8) Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006; 113: 1071-8.

9) Fattahi F, Ward PA. Complement and sepsis-induced heart dysfunction. Mol Immunol 2017; 84: 57-64.

10) Teixeira RP, Neves AL, Guimarães H. Cardiac biomarkers in neonatology: BNP/NTproBNP, troponin I/T, CK-MB and myoglobin-a systematic review. J Pediatr Neonatal Individual Med (JPNIM) 2017; 6: e060219.

11) El-Khuffash AF, Molloy EJ. Serum troponin in neonatal intensive care. Neonatology 2008; 94: 1-7.

12) Ozdemir OMA, Erdal B, Turgut M. Evaluation of Ema, Töllner and Rodwell scores in the diagnosis of neonatal sepsis. Pam Med J 2024; 17: 746-54.

13) Giannoni E, Agyeman PKA, Stocker M et al; Swiss Pediatric Sepsis Study. Neonatal sepsis of early onset, and hospital-acquired and community-acquired late onset: a prospective population-based cohort study. J Pediatr 2018; 201: 106-14.e4.

14) Cesur S, Irmak H, Eras Z et al. Prognostic value of serum TNF-alpha, IL-10, leptin and CRP levels in newborns with septicemia. Mikrobiyol Bul 2009; 43: 607-12.

15) Morad EA, Rabie RA, Almalky MA, Gebriel MG. Evaluation of procalcitonin, C-reactive protein, and interleukin-6 as early markers for diagnosis of neonatal sepsis. Int J Microbiol 2020; 2020: 8889086.

16) Rodrigues Wilde MO, Mezadri T, Gouveia PB, Grillo LP, Valete C. Prediction of early-onset neonatal sepsis in umbilical cord blood analysis: an integrative review. J Matern Fetal Neonatal Med 2022; 35: 10187-98.

17) Vijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. Use of cardiac biomarkers in neonatology. Pediatr Res 2012; 72: 337-43.

18) Yellanthoor RB, Rajamanickam D. Correlation of cardiac troponin T levels with inotrope requirement, hypoxic-ischemic encephalopathy, and survival in asphyxiated neonates. World J Clin Pediatr 2022; 11: 85-92.

19) Cruz MA, Bremmer YA, Porter BO, Gullquist SD, Watterberg KL, Rozycki HJ. Cardiac troponin T and cardiac dysfunction in extremely low-birth-weight infants. Pediatr Cardiol 2006; 27: 396-401.

20) Vijlbrief DC, Benders MJ, Kemperman H, van Bel F, de Vries WB. Cardiac biomarkers as indicators of hemodynamic adaptation during postasphyxial hypothermia treatment. Neonatology 2012; 102: 243-8.

21) Antonucci E, Fiaccadori E, Donadello K, Taccone FS, Franchi F, Scolletta S. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care 2014; 29: 500-11.

22) Vallabhajosyula S, Pruthi S, Shah S, Wiley BM, Mankad SV, Jentzer JC. Basic and advanced echocardiographic evaluation of myocardial dysfunction in sepsis and septic shock. Anaesth Intensive Care 2018; 46: 13-24.

23) Ammann P, Fehr T, Minder EI, Günter C, Bertel O. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27: 965-9.

24) Peek SF, Apple FS, Murakami MA, Crump PM, Semrad SD. Cardiac isoenzymes in healthy Holstein calves and calves with experimentally induced endotoxemia. Can J Vet Res 2008; 72: 356-61.

25) Oliveira NS, Silva VR, Castelo JS, Elias-Neto J, Pereira FE, Carvalho WB. Serum level of cardiac troponin I in pediatric patients with sepsis or septic shock. Pediatr Crit Care Med 2008; 9: 414-7.

26) Frencken JF, Donker DW, Spitoni C et al. Myocardial injury in patients with sepsis and its association with long-term outcome. Circ Cardiovasc Qual Outcomes 2018; 11: e004040.

27) Zheng P, Wang X, Guo T et al. Cardiac troponin as a prognosticator of mortality in patients with sepsis: A systematic review and meta-analysis. Immun Inflamm Dis 2023; 11: e1014.

28) Beydilli Y, Gökçe Hİ. Investigations of cardiac functions and organ damages in neonatal calves with suscepted sepsis. MAE Vet Fak Derg 2020; 5: 140-5.

29) Kırbaş A, Değirmençay Ş, Kilinç AA, Eroğlu MS. Increased Cardiac Troponin-I Concentration and Cardiac Enzyme Activities in Neonatal Calves with Sepsis. 2nd International Veterinary Internal Medicine Congress, Ankara, Turkey, 2019.